Compare ARES & MDLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARES | MDLN |
|---|---|---|
| Founded | 1997 | 1966 |
| Country | United States | United States |
| Employees | N/A | 45000 |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1B | 31.0B |
| IPO Year | 2014 | 2025 |
| Metric | ARES | MDLN |
|---|---|---|
| Price | $142.07 | $35.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 23 |
| Target Price | ★ $165.50 | $50.48 |
| AVG Volume (30 Days) | 2.3M | ★ 7.2M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | $4,755,618,000.00 | ★ $28,432,000,000.00 |
| Revenue This Year | N/A | $10.88 |
| Revenue Next Year | $17.59 | $7.69 |
| P/E Ratio | ★ $78.35 | $150.65 |
| Revenue Growth | ★ 28.86 | 11.47 |
| 52 Week Low | $95.80 | $32.49 |
| 52 Week High | $186.85 | $50.88 |
| Indicator | ARES | MDLN |
|---|---|---|
| Relative Strength Index (RSI) | 59.66 | 47.46 |
| Support Level | $139.43 | $35.07 |
| Resistance Level | $147.93 | $37.79 |
| Average True Range (ATR) | 4.44 | 1.26 |
| MACD | -0.52 | 0.14 |
| Stochastic Oscillator | 49.53 | 78.67 |
Ares Management is one of the world's largest alternative-asset managers, with $622.5 billion in total assets under management, or AUM, including $384.9 billion in fee-earning AUM, at the end of 2025. The company has four main business segments: credit strategies ($406.9 billion in total AUM and $249.8 billion in fee-earning AUM), private equity, ($25.3 billion/$14.4 billion), real estate/real assets ($139.1 billion/$84.1 billion), and other alternatives ($51.2 billion/$36.6 billion). The firm primarily serves institutional investors (80% of AUM) and high-net-worth individuals (20%). Ares operates through more than 35 offices in over 15 countries around the globe.
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.